Tumor-promoting/progressing role of additional chromosome instability in hepatic carcinogenesis in Sgo1 (Shugoshin 1) haploinsufficient mice

Carcinogenesis. 2015 Apr;36(4):429-40. doi: 10.1093/carcin/bgv011. Epub 2015 Mar 4.

Abstract

A major etiological risk factor for hepatocellular carcinoma (HCC) is infection by Hepatitis viruses, especially hepatitis B virus and hepatitis C virus. Hepatitis B virus and hepatitis C virus do not cause aggressive activation of an oncogenic pathway, but they transactivate a broad array of genes, cause chronic inflammation, and, through interference with mitotic processes, lead to mitotic error-induced chromosome instability (ME-CIN). However, how ME-CIN is involved in the development of HCC remains unclear. Delineating the effect of ME-CIN on HCC development should help in identifying measures to combat HCC. In this study, we used ME-CIN model mice haploinsufficient in Shugoshin 1 (Sgo1(-/+)) to assess the role of ME-CIN in HCC development. Treatment with the carcinogen azoxymethane caused Sgo1(-/+) ME-CIN model mice to develop HCCs within 6 months, whereas control mice developed no HCC (P < 0.003). The HCC development was associated with expression of early HCC markers (glutamine synthetase, glypican 3, heat shock protein 70, and the serum marker alpha fetoprotein), although without fibrosis. ME-CIN preceded the expression of HCC markers, suggesting that ME-CIN is an important early event in HCC development. In 12-month-old untreated Sgo1 mice, persistent DNA damage, altered gene expression, and spontaneous HCCs were observed. Sgo1 protein accumulated in response to DNA damage in vitro. Overall, Sgo1(-/+)-mediated ME-CIN strongly promoted/progressed development of HCC in the presence of an initiator carcinogen, and it had a mild initiator effect by itself. Use of the ME-CIN model mice should help in identifying drugs to counteract the effects of ME-CIN and should accelerate anti-HCC drug development.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Azoxymethane / pharmacology
  • Carcinogens / pharmacology
  • Carcinoma, Hepatocellular / chemically induced
  • Carcinoma, Hepatocellular / genetics*
  • Cell Cycle Proteins / genetics*
  • Cell Line, Tumor
  • Cell Transformation, Neoplastic / chemically induced
  • Cell Transformation, Neoplastic / genetics*
  • Chromosomal Instability / genetics*
  • DNA Damage / genetics
  • Female
  • Glutamate-Ammonia Ligase / biosynthesis
  • Glypicans / biosynthesis
  • HSP70 Heat-Shock Proteins / biosynthesis
  • Haploinsufficiency / genetics
  • HeLa Cells
  • Hep G2 Cells
  • Hepacivirus / pathogenicity
  • Hepatitis B virus / pathogenicity
  • Humans
  • Liver Neoplasms / chemically induced
  • Liver Neoplasms / genetics*
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Mitosis / genetics
  • alpha-Fetoproteins / biosynthesis

Substances

  • Carcinogens
  • Cell Cycle Proteins
  • GPC3 protein, human
  • Glypicans
  • HSP70 Heat-Shock Proteins
  • alpha-Fetoproteins
  • shugoshin protein, mouse
  • Glutamate-Ammonia Ligase
  • Azoxymethane